Company Description

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.

It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.

The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose.

Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Nasus Pharma Ltd.

Country	Israel
Founded	2019
IPO Date	Aug 14, 2025
Industry	Drug Manufacturers - General
Sector	Healthcare
Employees	7
CEO	Brendan O'Grady

Contact Details

Address: Yigal Alon 65 Tel Aviv-Yafo, 6744317 Israel
Phone	972 3 573 6632
Website	nasuspharma.com

Stock Details

Ticker Symbol	NSRX
Exchange	NYSEAMERICAN
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$8.00
CIK Code	2029039
ISIN Number	IL0012181553
Employer ID	51-6022712
SIC Code	2834

Key Executives

Name	Position
Brendan P. O'Grady	Chief Executive Officer and Director
Ehud Moshe Gilboa MBA	Co-Founder and Executive Chairman
Dr. Dalia Megiddo M.B.A., M.D., Ph.D.	Co-Founder, Director, Chief Medical Officer and Chief Development Officer?
Oren Elmaliach	Director of Finance and Interim Chief Financial Officer
Dr. Galia Temtsin Kryaz Ph.D.	Director of CMC and Product Development

Latest SEC Filings

Date	Type	Title
Oct 19, 2026	S-8	Securities to be offered to employees in employee benefit plans
Oct 8, 2026	6-K	Report of foreign issuer
Sep 18, 2026	424B5	Filing
Sep 18, 2026	6-K	Report of foreign issuer
Sep 14, 2026	6-K	Report of foreign issuer
Sep 11, 2026	EFFECT	Notice of Effectiveness
Sep 4, 2026	6-K	Report of foreign issuer
Sep 1, 2026	F-3	Filing
Aug 20, 2026	EFFECT	Notice of Effectiveness
Aug 19, 2026	6-K	Report of foreign issuer

View All SEC Filings